Daniel A. Pollyea, MD, on the Impact of Venetoclax in IDH-Mutant AML


The leukemia expert discussed the clinical implications of findings demonstrating improved response for patients with acute myeloid leukemia with IDH mutations.

In an interview with CancerNetwork®, Daniel A. Pollyea, MD, of the University of Colorado Cancer Center, discusses the clinical implications of a pooled analysis examining treatment with venetoclax (Venclexta) and azacitidine (Vidiza) versus azacitidine alone for patients with acute myeloid leukemia with IDH mutations.


The clinical observation that we’re making here [is that this trial] opens the door very clearly for folks in the community to figure out, “why is it that venetoclax and IDH [mutations] go so well together? And if we can figure that out, is it possible then to tweak the IDH wild-type [tumors] and recapitulate the results that we see in [this setting] so that in the future, all patients, regardless of IDH status, could have this type of response to venetoclax, maybe by adding another drug into the mix or something along those lines.

Related Videos
Mikkael A. Sekeres, MD, discusses how data from the phase 3 QuANTUM-First trial may advance the treatment field for patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.
An expert from Duke Health says that patients with NPM1-mutatant relapsed/refractory acute myeloid leukemia did not experience any significant safety signals following treatment with ziftomenib.
At the recommended 600 mg dose, ziftomenib interestingly produced complete remissions in patients relapsed/refractory acute myeloid leukemia who harbored NPM1 mutations .
An expert from Duke Health reviews the design of the phase 1/2 trial of the KOMET-001 study in heavily pretreated patients with relapsed/refractory acute myeloid leukemia.